Skip to content

Clinical study of fibroblast activating protein inhibitor (FAPI)-mediated 18F targeted to evaluate inflammation and fibrosis in renal diseases

Clinical study of fibroblast activating protein inhibitor (FAPI)-mediated 18F targeted to evaluate inflammation and fibrosis in renal diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065996
Enrollment
Unknown
Registered
2022-11-21
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal inflammation and fibrosis

Interventions

Gold Standard:Renal puncture biopsy
Index test:18F-FAPI PET/CT examination

Sponsors

Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 60 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosis of renal inflammation or fibrosis disease.

Exclusion criteria

Exclusion criteria: 1. Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160 mmHg; 2. Renal biopsy cannot be performed for severe exclotting disease; 3. Complicated with chronic liver disease, myocardial infarction, stroke, and malignant tumor; 4. Unable to cooperate with renal puncture biopsy due to language communication or other problems; 5. Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception; 6. Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes; 7. Alcohol allergy; 8. Patients with significant decrease in urine volume due to disease; 9. Refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved protocol; 10. Other circumstances deemed inappropriate by the investigator for participation in the study.

Design outcomes

Primary

MeasureTime frame
Standardized uptake value;

Countries

China

Contacts

Public ContactYunlin Feng

Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital

fengyunlin@med.uestc.edu.cn+86 17708130285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026